Drug Profile
MK 7252
Alternative Names: MK-7252Latest Information Update: 28 Dec 2020
Price :
$50
*
At a glance
- Originator Merck Sharp & Dohme
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Dec 2020 No recent reports of development identified for phase-I development in Cancer(In volunteers) in Belgium (PO, Suspension)
- 17 Dec 2018 Merck completes a phase-I trial in Cancer (In volunteers) in Belgium (PO) (NCT03326986)
- 10 Nov 2017 Phase-I clinical trials in Cancer (In volunteers) in Belgium (PO) (NCT03326986)